The estrogen receptor ER and progesterone receptor PR are present in normal female breast cells, and estrogen and progesterone regulate cellular functions through ER and PR. When the cells are malignant, the tumor cells may partially or completely retain the normal receptor system, and their cell growth still depends on the original hormonal environment regulation, which is called hormone-dependent tumor, clinically known as ER-positive breast cancer. In the process of carcinoma, the cells retain little or no receptor system and can no longer serve as hormone target cells, and their growth is no longer controlled and regulated by hormones. The formation of PR is controlled and regulated by ER, so most of the PR-positive breast cancers are ER-positive. ER and PR are closely related to the prognosis of breast cancer patients, guiding endocrine therapy and predicting the responsiveness of breast cancer to hormone therapy. Tumors without ER or PR expression are usually poorly responsive to hormone therapy, while ER and PR positive tumors are highly responsive to hormone therapy, i.e., blocking hormone action can achieve the purpose of treating tumors. PS2 protein is one of the estrogen-inducible proteins, and PS2 gene is regulated and controlled by estrogen, and can only be transcribed under estrogen induction and control. c-erbB-2 is valuable in determining prognosis and guiding endocrine therapy, and positive tumors have good prognosis, low recurrence and mortality rates, and effective endocrine therapy. The c-erbB-2 oncogene is a common and easily activated proto-oncogene in breast tissue cells. Its amplification or overexpression is restricted to cancer cells but not to normal breast epithelium, and is also significantly associated with breast cancer recurrence, metastasis and survival. Overexpression of c-erbB-2 is an important factor in poor prognosis, as it increases the rate of early postoperative recurrence and distant metastasis and shortens survival. Ki67 is associated with tumor cell proliferation, and simple type mucinous carcinoma generally has low proliferative activity.